Posttranscriptional Regulation in Eukaryotes: Mechanisms and Implications

Study Guide - Smart Notes

Tailored notes based on your materials, expanded with key definitions, examples, and context.

Posttranscriptional Gene Regulation

Overview of Posttranscriptional Regulation

Posttranscriptional regulation refers to the control of gene expression after transcription has occurred, encompassing all processes that modify or influence the fate of RNA transcripts. In eukaryotes, these mechanisms are essential for generating protein diversity, regulating gene expression, and responding to cellular signals.

Key Mechanisms: Alternative splicing, mRNA stability, translation control, and RNA silencing.
Significance: These processes allow a single gene to produce multiple protein isoforms and enable rapid adaptation to environmental or developmental cues.

Overview of posttranscriptional regulation: chromatin remodeling, transcription, splicing, mRNA export, translation, and protein modification

RNA Processing in Eukaryotes

Pre-mRNA Processing Steps

Eukaryotic mRNA is initially synthesized as a precursor (pre-mRNA) that undergoes several modifications before becoming a mature, translatable mRNA.

5' Capping: Addition of a 7-methylguanosine cap to the 5' end, protecting the RNA and facilitating translation initiation.
Splicing: Removal of non-coding introns and joining of coding exons.
3' Polyadenylation: Addition of a poly(A) tail to the 3' end, enhancing stability and export.

Diagram of pre-mRNA processing: capping, splicing, and polyadenylation

5' Cap Structure

The 5' cap structure is a unique feature of eukaryotic mRNAs, consisting of a 7-methylguanosine linked via a 5'-5' triphosphate bridge to the first nucleotide of the RNA.

Function: Protects mRNA from exonuclease degradation and is recognized by cap-binding proteins during translation initiation.

Chemical structure of the 5' m7G cap on mRNA

Exons and Introns

Genes in eukaryotes are typically interrupted by introns (non-coding regions) interspersed among exons (coding regions). The length and number of introns and exons can vary widely among genes and species.

Exons: Typically 25–300 nucleotides in humans; encode protein sequences.
Introns: Range from hundreds to tens of thousands of nucleotides; removed during splicing.

Comparison of exon and intron lengths in mouse insulin, rabbit beta-globin, and chicken ovalbumin genes

RNA Splicing Mechanisms

Types of Introns

Introns are classified based on their splicing mechanisms:

Group I Introns: Self-splicing ribozymes; use a free guanosine as a cofactor.
Group II Introns: Self-splicing; form a lariat intermediate via a branch-point adenosine.
Spliceosomal Introns: Require the spliceosome, a complex of snRNPs and proteins, for removal; most common in nuclear genes.

Group I intron splicing mechanism Group II intron splicing mechanism with lariat formation

Spliceosome-Mediated Splicing

The spliceosome recognizes conserved sequences at the 5' (GU) and 3' (AG) splice sites and the branch-point adenosine. Splicing occurs via two transesterification reactions, resulting in exon ligation and intron removal as a lariat.

snRNPs: U1, U2, U4, U5, and U6 are essential for splice site recognition and catalysis.
Splicing Steps: Assembly, activation, lariat formation, exon ligation, and disassembly.

Spliceosome assembly and splicing steps

Alternative Splicing

Mechanisms and Biological Significance

Alternative splicing allows a single gene to produce multiple mRNA and protein isoforms by varying the combination of exons included in the mature transcript. This process greatly expands proteomic diversity without increasing gene number.

Regulation: Controlled by cis-acting elements (enhancers/silencers) and trans-acting splicing factors (e.g., SR proteins, hnRNPs).
Prevalence: Over two-thirds of human protein-coding genes undergo alternative splicing.

Types of alternative splicing: cassette exons, alternative splice sites, intron retention, mutually exclusive exons, alternative promoters, and alternative polyadenylation

Example: Calcitonin/CGRP Gene

The calcitonin/CGRP gene produces two distinct peptides via alternative splicing and polyadenylation in different tissues.

Thyroid cells: Include exon 4, producing calcitonin.
Neuronal cells: Include exons 5 and 6, producing CGRP.

Alternative splicing of the calcitonin/CGRP gene transcript

Regulation of Alternative Splicing

Alternative splicing is regulated by the interplay of cis-acting RNA elements and trans-acting proteins. Enhancers and silencers can be located in exons or introns, and their binding by specific proteins determines splice site usage.

Enhancers: Exonic (ESE) or intronic (ISE) sequences that promote splicing.
Silencers: Exonic (ESS) or intronic (ISS) sequences that repress splicing.
Splicing Factors: SR proteins (activators) and hnRNPs (repressors) modulate spliceosome assembly and activity.

Diagram of splicing enhancers, silencers, and associated proteins

Alternative Splicing in Drosophila Sex Determination

Sex Determination Pathway

In Drosophila, sex is determined by the ratio of X chromosomes to autosomes, interpreted by a cascade of alternative splicing events involving the Sex lethal (Sxl), transformer (tra), and doublesex (dsx) genes.

Female (XX): Sxl protein is produced, leading to functional Tra protein and female-specific DsxF isoform.
Male (XY): No Sxl protein, default splicing produces truncated Tra and male-specific DsxM isoform.

Alternative splicing pathway for Drosophila sex determination Sxl and U2AF competition at the tra pre-mRNA splice site Tra-dependent alternative splicing of dsx pre-mRNA Tra, Tra2, and SR proteins promoting female-specific dsx splicing

Spliceopathies: Genetic Disorders of Splicing

Myotonic Dystrophy

Myotonic dystrophy (DM) is a spliceopathy caused by repeat expansions in the DMPK (DM1) or CNBP (DM2) genes, leading to disrupted splicing regulation and multisystemic symptoms.

DM1: CTG repeat expansion in DMPK gene.
DM2: CCTG repeat expansion in CNBP gene.

Spinal Muscular Atrophy (SMA)

SMA is an autosomal recessive neuromuscular disorder caused by loss of function in both copies of the SMN1 gene. The nearly identical SMN2 gene can partially compensate, but a single nucleotide change leads to exon 7 skipping in most transcripts, producing unstable protein.

Inheritance: Autosomal recessive; both parents must carry the mutation.
Therapy: Spinraza (nusinersen) is an antisense oligonucleotide that promotes exon 7 inclusion in SMN2 transcripts, restoring functional SMN protein.

Normal vs. SMA-affected nerve and muscle cell Autosomal recessive inheritance pattern SMN1 and SMN2 gene structure and splicing outcomes Spinraza mechanism: antisense oligo promotes exon 7 inclusion in SMN2 Timeline and mechanism of Spinraza therapy for SMA

Control of mRNA Stability

mRNA Capping and Polyadenylation

mRNA stability is influenced by the presence of a 5' cap and a 3' poly(A) tail. The cap protects against 5'→3' exonucleases, while the poly(A) tail and associated binding proteins protect against 3'→5' degradation.

Decapping: Removal of the cap exposes the mRNA to degradation by XRN1.
Deadenylation: Shortening of the poly(A) tail precedes mRNA decay.

mRNA capping process mRNA capping process (alternate view) Chemical structure of the 5' m7G cap on mRNA mRNA decay pathways: decapping and deadenylation

Alternative Polyadenylation

Many genes have multiple polyadenylation sites, allowing the production of mRNA isoforms with different 3' UTRs. This can affect mRNA stability, localization, and translation by including or excluding regulatory elements.

Regulation: Controlled by processing factors such as CstF64 and sequence elements in the pre-mRNA.

Alternative polyadenylation sites in mRNA Alternative last-exon selection and polyadenylation

mRNA Surveillance and Decay Pathways

Nonsense-Mediated Decay (NMD)

NMD is a quality control mechanism that degrades mRNAs containing premature termination codons (PTCs), preventing the production of truncated, potentially harmful proteins.

Mechanism: Exon junction complexes (EJCs) mark splice sites; if translation terminates upstream of an EJC, NMD is triggered.

Nonsense-mediated decay pathway

RNA Silencing and Noncoding RNAs

RNA Interference (RNAi)

Small noncoding RNAs, including siRNAs and miRNAs, regulate gene expression posttranscriptionally by guiding the RNA-induced silencing complex (RISC) to target mRNAs for degradation or translational repression.

siRNAs: Derived from long double-stranded RNA; direct cleavage of perfectly complementary targets.
miRNAs: Derived from hairpin precursors; typically repress translation or promote decay via partial complementarity.

Mechanism of RNA-induced gene silencing by small non-coding RNAs siRNA antiviral defense mechanism microRNA biogenesis and function

Long Noncoding RNAs (lncRNAs)

lncRNAs are transcripts longer than 200 nucleotides that do not encode proteins but regulate gene expression through diverse mechanisms, including chromatin remodeling, splicing modulation, mRNA stability, and miRNA sponging.

Classes: Antisense, intronic, bidirectional, and intergenic lncRNAs.
Functions: Guide chromatin modifiers, act as decoys, scaffolds, or guides, and regulate mRNA processing and translation.

Types of lncRNA loci Mechanisms of lncRNA function

Translational and Posttranslational Regulation

Cytoplasmic Polyadenylation and mRNA Localization

Some mRNAs are stored in a translationally repressed state and activated by cytoplasmic polyadenylation in response to specific signals. Localization elements (zip codes) in the 3' UTR direct mRNAs to specific cellular regions, where translation is locally activated.

Closed loop translation: interaction of cap and poly(A) tail Cytoplasmic polyadenylation and translational activation mRNA localization and translational control

Posttranslational Modifications

Protein activity and stability are further regulated after translation by modifications such as phosphorylation and ubiquitination.

Phosphorylation: Addition of phosphate groups by kinases; removal by phosphatases. Alters protein conformation and function.
Ubiquitination: Covalent attachment of ubiquitin targets proteins for degradation by the proteasome.

Ras–MAP kinase pathway and phosphorylation cascade Ubiquitin-mediated protein degradation pathway

Regulation of p53 Protein

The tumor suppressor p53 is regulated by ubiquitin-mediated degradation. Under normal conditions, Mdm2 ubiquitinates p53, targeting it for proteasomal degradation. Upon DNA damage, Mdm2 is phosphorylated and loses affinity for p53, allowing p53 accumulation and activation of cell cycle arrest and DNA repair genes.

Ubiquitination and regulation of p53 protein